Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 2
Metronomic Decitabine-Cedazuridine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia R/R AML), High Risk Myelodysplastic Syndrome (HR-MDS), and High-Risk Myeloproliferative Neoplasms (HR/AP MPN)
This is a single-center randomized phase 2 open-label clinical trial.
Relapsed / Refractory AMLHigh Risk Myelodysplastic SyndromeHigh Risk Myeloproliferative Neoplasms
Estimated
~$10 – $6,250
Virginia Commonwealth UniversityNCT07710534
Phase 2
Pilot Single Arm Phase 2 Study of Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
This is a prospective, single-arm phase 2 pilot study to assess the response rate of IDH1 mutated relapsed/refractory acute myeloid leukemia (AML) patients who…
IDH1 MutationRelapsed / Refractory AML
Estimated
~$10 – $7,500
Timothy PardeeNCT07471841